• Flanders Investment & Trade
  • Team Vesalius

A biochemist by training, Chris De Jonghe is the current valorization director at the Dutch Oncode Institute for cancer research.

Chris De Jonghe

Oncode Institute

Valorization Director

Previously, De Jonghe worked for more than 10 years in the tech transfer team of the Flanders Institute for Biotechnology (VIB), where she was involved in research collaborations, IP licensing and new venture creation. She used to be the head of Life Sciences & Care and group manager of Venture Capital at investment company PMV, where she was a member of its management committee.

De Jonghe obtained her PhD in the field of neurodegeneration and holds a law degree as well. She serves on the boards of several operational life sciences companies, investment funds and cluster organizations.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?